Table 2.
Comparison of clinical characteristics according to PD-L1 expression
| Characteristics | All patients (N = 125) | PD-L1 PE (N = 89) | PD-L1 NE (N = 36) | P value |
|---|---|---|---|---|
| Age, mean (range) (years) | 54.49 (27–80) | 58.85 (27–76) | 57.58 (32–80) | 0.451 |
| Gender, n (%) | 0.955 | |||
| Male | 63 (50.4) | 45 (50.6) | 18 (50.0) | |
| Female | 62 (49.6) | 44 (49.4) | 18 (50.0) | |
| Smoking status, n (%) | 0.206 | |||
| Never | 87 (69.6) | 59 (66.3) | 28 (77.8) | |
| Smoker | 38 (30.4) | 30 (33.7) | 8 (22.2) | |
| Location, n (%) | 0.840 | |||
| Right upper lobe | 46 (36.8) | 31 (34.8) | 15 (41.7) | |
| Right middle lobe | 7 (5.6) | 6 (6.7) | 1 (2.8) | |
| Right lower lobe | 24 (19.2) | 17 (19.1) | 7 (19.4) | |
| Left upper lobe | 34 (27.2) | 24 (27.0) | 10 (27.8) | |
| Left lower lobe | 14 (11.2) | 11 (12.4) | 3 (8.3) | |
| CT pattern, n (%) | 0.713 | |||
| Pure solid nodule | 68 (54.4) | 48 (53.9) | 20 (55.6) | |
| Part-solid nodule | 46 (36.8) | 32 (36.0) | 14 (38.9) | |
| Ground glass nodules | 11 (8.8) | 9 (10.1) | 2 (5.5) | |
| Diameter of nodule, mean (range) (cm) | 1.66 (0.4–6.4) | 1.66 (0.4–6.4) | 1.65 (0.6–6.2) | 0.372 |
| Histological type, n (%) | 0.522 | |||
| LAC | 115 (92.0) | 81 (91.0) | 34 (94.4) | |
| LSC | 10 (8.0) | 8 (9.0) | 2 (5.6) | |
| Stage, n (%) | 0.909 | |||
| Tis | 4 (3.2) | 3 (3.4) | 1 (2.8) | |
| I | 106 (84.8) | 76 (85.4) | 30 (83.3) | |
| II and III | 15 (12.0) | 10 (11.2) | 5 (13.9) | |
| EGFR gene, n (%) | 0.695 | |||
| Mutant-type | 66(52.8) | 46 (51.7) | 20 (55.6) | |
| Wild-type | 59(47.2) | 43 (48.3) | 16 (44.4) | |
| Ki-67 expression, n (%) | 0.109 | |||
| Positive | 41 (32.8) | 33 (37.1) | 8 (22.2) | |
| Negative | 84 (67.2) | 56 (62.9) | 28 (77.8) |
Differences were assessed by Mann–Whitney U test or Chi-squared test
PD-L1 programmed cell death protein ligand 1, PE positive expression, NE negative expression, LAC lung adenocarcinoma, LSC lung squamous carcinoma, EGFR epidermal growth factor receptor